Evidence map›Paper›PMID 33587767›Full record

ArticleJournal of clinical apheresis2021

Donor tolerability of convalescent plasma donation.

Rui He, Hui Lin, Songli Xie, Qilu Lv, Yujie Kong, Ling Li, Haixia Xu, Jue Wang, Wenjuan Li, Peng Fang and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical apheresis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Donor tolerability of convalescent plasma donation.Journal of clinical apheresis · 2021
    Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Rui HeClinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan Province, P.R. China.
Hui LinBlood Collection Center, Wuhan Blood Center, Wuhan, Hubei Province, P.R. China.
Songli XieBlood Collection Center, Wuhan Blood Center, Wuhan, Hubei Province, P.R. China.
Qilu LvClinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan Province, P.R. China.
Yujie KongClinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan Province, P.R. China.
Ling LiClinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan Province, P.R. China.
Haixia XuClinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan Province, P.R. China.
Jue WangClinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan Province, P.R. China.
Wenjuan LiSchool of Public Health, Anhui Medical University, Hefei, China.
Peng FangSchool of Public Health, Anhui Medical University, Hefei, China.
Yanyun WuClinical Transfusion Center, University of Miami, Miami, Florida, USA.
Zhong LiuClinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan Province, P.R. China.ORCID https://orcid.org/0000-0001-8791-2341
Chinese Academy of Medical Sciences & Peking Union Medical College · CNAnhui Medical University · CNWuhan Blood Center · CNUniversity of Miami · US

Funding

the CAMS Innovation Fund for Medical Sciences (CIFMS) 2016-I2M-3-024the CAMS Innovation Fund for Medical Sciences (CIFMS) 2017-I2M-1-009the CAMS Innovation Fund for Medical Sciences (CIFMS) 2020-I2M-CoV19-006
6 · The paper itself

Abstract

backgroundSince early 2020, convalescent plasma has been widely used for treating coronavirus disease 2019 (COVID-19). There is limited information regarding donor tolerability of convalescent plasma donation. In this study, we evaluated the short-term donor tolerability of convalescent plasma donation.

methodsA prospective study of 309 convalescent plasma donation related adverse events were conducted at Wuhan Blood Center of China, from February 12 to April 1, 2020. Additionally, up to 28-day post-donation follow-ups were performed on the donors.

resultsSixteen (5.2%) adverse events were reported in 309 donations. All of these were mild vasovagal without loss of consciousness. The frequency of adverse reactions was higher in donors with a per donation volume of >8 mL/kg body weight or ≥ 600 mL, <100 mm Hg in pre-donation systolic blood pressure, or less than 28 days from the onset of COVID-19 symptoms. There was no correlation to donation history, weight, sex, ABO blood type, pre-donation diastolic blood pressure, pulse, or hemoglobin.

conclusionThe donation of convalescent plasma is generally safe. Mitigation of risk factors associated with adverse events can further enhance donor tolerability of convalescent plasma donation.

Indexed as

Blood DonorsPlasmaAdultChinaConvalescenceCOVID-19COVID-19 SerotherapyFemaleFollow-Up StudiesHumansImmunization, PassiveMaleMiddle AgedProspective StudiesRisk FactorsYoung Adultadverse donation reactionconvalescent plasmacoronavirus disease 2019

Identifiers

PMID33587767
PMCPMC8013347
OpenAlexW3129724075

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.